Australian company Medlab Clinical Limited is preparing to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.
The trial will see patients given a specially prepared formulation, called Nanabis. It is made up of the two most well-known cannabis extracts, CBD (cannabidiol) and THC (tetrahydrocannabinol) and will be administered via the firm’s NanoCelle system – a tiny particle mouth spray for medicine.
Medlab managing director Sean Hall told the company’s recent annual general meeting that the trial would take place at Royal North Shore Hospital in Sydney under the supervision of Professor Stephen Clarke OAM, a medical oncologist, palliative medicine specialist and Professor of Medicine at the University of Sydney.
And today the company was granted a licence to import cannabis from the Australian Department of Health/Therapeutic Goods Administration (TGA).
Medlab managing director Sean Hall, said this was a significant milestone for the firm.
“It shows we have satisfied TGA